LEXINGTON, Mass.--(BUSINESS WIRE)--Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company focused on discovering, developing, and commercializing small molecule drugs to treat severe medical conditions, today announced that the first patient has been treated in its clinical trial of STA-9090 in combination with docetaxel for the treatment of advanced solid tumor malignancies. This is the first clinical trial of STA-9090, a potent second-generation, small-molecule Hsp90 inhibitor with a chemical structure unrelated to the first-generation, ansamycin family of Hsp90 inhibitors (e.g., 17-AAG or IPI-504), in combination with another anti-cancer agent. Recent studies support synergistic anti-cancer activity of taxanes and Hsp90 inhibitors[1-9].
